NCT02497976View on ClinicalTrials.gov

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

PHASE3CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

December 15, 2015

Primary Completion Date

April 16, 2017

Study Completion Date

July 12, 2017

Conditions

Cystitis, Interstitial

Interventions

BIOLOGICAL

Certolizumab pegol

400 mg

DRUG

Placebo

Normal saline

Trial Locations (1)

92025

Philip C. Bosch, MD, Escondido

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

UCB Pharma

INDUSTRY

lead

ICStudy, LLC

OTHER